State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF (XPH)
- Fund company
- SPDR Series Trust
- Fund net assets
- $428.4M
- Equity lines
- 65
- Holdings as of
- 30 June 2026
- Source
- N-PORT report, SEC →
Weighted score of the companies held
So far, 6% of the fund is scored by Scorvest. The score is published once more than 50% is: the missing companies are being added.
–
- Profitability
- –
- Balance sheet
- –
- Cash generation
- –
- Stability
- –
- Growth
- –
Fund split by score
- Scored 75+ 1%
- Scored 40–74 5%
- Scored below 40 0%
- Not scored yet 94%
Sectors
Countries
Top holdings
| Company | Weight | Score | |
|---|---|---|---|
| Definium Therapeutics Inc | 3.09% | pending | |
| MBX Biosciences Inc | 2.72% | pending | |
| Alumis Inc | 2.14% | pending | |
| AtaiBeckley Inc | 2.13% | pending | |
| Trevi Therapeutics Inc | 2.12% | pending | |
| Enliven Therapeutics Inc | 2.09% | pending | |
| Amylyx Pharmaceuticals Inc | 2.04% | pending | |
| VeraDermics Inc | 2.02% | pending | |
| Ligand Pharmaceuticals Inc | 1.94% | pending | |
| Nuvation Bio Inc | 1.89% | pending | |
The next 40 holdings are visible from the Essential plan. Try free for 7 days → | |||
Computed from the equity lines reported by the fund. Weights are those of the N-PORT report at the date shown. General information, not investment advice.